COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,705 Articles (22,913 medRxiv, 8,792 bioRxiv)

Most recent first Previous |  Page 146: Articles 1451-1460  | Next

Immunological and clinical markers of post-acute sequelae of COVID-19: Insights from mild and severe cases six months post-infection
Mouton, W., Djebali, S., Villard, M., Allatif, O., Chauvel, C., Benezech, s., Vanhems, p., MARVEL, J., Walzer, T., Trouillet-Assant, S.
10.1101/2025.02.18.638851 — Posted: 2025-02-21
Active vaccine safety surveillance: Experience from a prospective cohort event monitoring study of COVID-19 vaccines in Kenya
Odhiambo, D. B., Akech, D., Karia, B., Kimani, M., Sang, S., Sigilai, A., Voller, S., Mataza, C., Mang'ong'o, D., Jalang'o, R., Mandale, M., Etyang, A. O., Scott, J. A. G., Agweyu, A., Kagucia, E. W.
10.1101/2025.02.18.25322051 — Posted: 2025-02-20
evoSSS: Modeling the Competitive Evolution and Large-scale Transmission Dynamics of SARS-CoV-2 and Emerging Viral Pathogens
Huang, S., Lu, X., Xiao, Z., Zhuang, Y., Wei, X., Fan, Z., Huang, L., Zhao, S., Lynch, M., Yao, H., Zheng, M., Jiang, C.
10.1101/2025.02.15.25322128 — Posted: 2025-02-20
Changed epidemiology of influenza and RSV hospitalizations after the emergence of SARS-CoV-2 in Norway, 2017 - 2024
Boas, H., Seppala, E. M., Veneti, L., Stalcrantz, J., Berild, J. D., Dahl, J., Paulsen, T. H.
10.1101/2025.02.17.25322411 — Posted: 2025-02-20
Anticoagulant vs. antiviral therapy, recovery and neurodamage in Long COVID: a real-world prospective cohort study
Jamoulle, M., Mignolet, M., Meyts, I., Ladang, A., Nicaise, C., Van Weyenbergh, J.
10.1101/2025.02.14.25322178 — Posted: 2025-02-20
Oral Cavity Serves as Long-Term COVID-19 Reservoir with Increased Periodontal and Viral Disease Risk
Schwartz, J., Capistrano, K., Naqvi, R., Elshourbagy, S., Hezarkhani, A., Etminan, S., Bland, J., Kadkol, S., Shukla, D., Nares, S., Tomar, S., Naqvi, A.
10.1101/2025.02.17.638734 — Posted: 2025-02-19
Likely circulation of a coronavirus in roe deer (Capreolus capreolus) populations suggested by SARS-CoV-2 serological investigation in France
Perez, G., Lalande, L. D., Legros, V., Kodjo, A., Verheyden, H., Bourret, V., Cebe, N., Chaval, Y., Revelli, P., Pellerin, M., Lemaitre, J.-F., Peroz, C., Rey, B., Debias, F., Garcia, R., Bourgoin, G., Gilot-Fromont, E.
10.1101/2025.02.19.639030 — Posted: 2025-02-19
Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primates
Sauter, K. A., Webb, G. M., Bader, L., Kreklywich, C. N., Takahashi, D. L., Zaro, C., McGuire, C. M., Lewis, A. D., Colgin, L. M. A., Kirigiti, M. A., Blomenkamp, H., Pessoa, C., Humkey, M., Hulahan, J., Sleeman, M., Zweig, R. C., Thomas, S., Thomas, A., Gao, L., Hirsch, A. J., Levy, M., Cherry, S. R., Kahn, S. E., Slifka, M. K., Sacha, J. B., Kievit, P., Roberts, C.
10.1101/2025.02.18.638792 — Posted: 2025-02-19
Evolution of BA.2.86 to JN.1 reveals functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2
Tsujino, S., Tsuda, M., Nao, N., Okumura, K., Wang, L., Oda, Y., Mimura, Y., Li, J., Hashimoto, R., Matsumura, Y., Suzuki, R., Suzuki, S., Yoshimatsu, K., Nagao, M., Ito, J., Takayama, K., Sato, K., Matsuno, K., Tamura, T., Tanaka, S., Fukuhara, T.
10.1101/2025.02.17.638623 — Posted: 2025-02-19
In a pathophysiologic state due to SARS-CoV-2, viscosity and cholesterol are two-edged swords.
Udema, I. I.
10.1101/2025.02.17.638432 — Posted: 2025-02-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).